Evidence map›Paper›PMID 32266542›Full record

ArticleJournal of neurology2020

Impact of comorbidities and co-medication on disease onset and progression in a large German ALS patient group.

Kristin Diekmann, Magdalena Kuzma-Kozakiewicz, Maria Piotrkiewicz, Marta Gromicho, Julian Grosskreutz, Peter M Andersen, Mamede de Carvalho, Hilmi Uysal, Alma Osmanovic, Olivia Schreiber-Katz and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 4 pooled it
2.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 4 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Medications on hypertension, hyperlipidemia, diabetes, and risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022 · on this map
    Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Prevalence and impact of comorbidities in amyotrophic lateral sclerosis.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  8. Type 2 diabetes mellitus, antidiabetics, and the risk of amyotrophic lateral sclerosis.Amyotrophic lateral sclerosis & frontotemporal degeneration · 2025
    Article
  9. Article
  10. Increased risk of ischemic stroke in amyotrophic lateral sclerosis: a nationwide cohort study in South Korea.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 5 countries.

Kristin DiekmannDepartment of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, C, Germany.
Magdalena Kuzma-KozakiewiczDepartment of Neurology, Medical University of Warsaw, Warsaw, Poland.
Maria PiotrkiewiczNalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences, Warsaw, Poland.
Marta GromichoFaculty of Medicine, Institute of Physiology-Instituto de Medicina Molecular, University of Lisbon, Lisbon, Portugal.
Julian GrosskreutzDepartment of Neurology, University Hospital Jena, Jena, Germany.
Peter M AndersenDepartment of Pharmacology and Clinical Neuroscience, Umeå University, Umeå, Sweden.
Mamede de CarvalhoFaculty of Medicine, Institute of Physiology-Instituto de Medicina Molecular, University of Lisbon, Lisbon, Portugal.
Hilmi UysalDepartment of Neurology, Faculty of Medicine, Akdeniz University, Antalya, Turkey.
Alma OsmanovicDepartment of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, C, Germany.
Olivia Schreiber-KatzDepartment of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, C, Germany.
Susanne PetriDepartment of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, C, Germany.
Sonja KörnerDepartment of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, C, Germany. koerner.sonja@mh-hannover.de.
Medizinische Hochschule Hannover · DEUniversity of Lisbon · PTAkdeniz University · TRInstitute of Biocybernetics and Biomedical Engineering · PLJena University Hospital · DEMedical University of Warsaw · PLUmeå University · SE

Funding

European Union ONWebDUALS project, JNPD 01ED1511B
6 · The paper itself

Abstract

introductionAmyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with loss of muscle function. The pathogenesis is still unclear and the heterogeneity of ALS phenotypes is huge. We investigated a large population of ALS patients and controls concerning comorbidities and medications to detect specific risk or protective factors regarding onset and progression of ALS.

methodsWe investigated a cohort of 200 ALS patients pro- and retrospectively compared to a control group. For comparison of frequencies of comorbidities and medication intake, uni- and multivariate binary logistic regressions were performed. To analyze the influence of comorbidities and medication on the progression of ALS, we used linear regression analysis.

resultsALS patients showed a relevantly higher prevalence of strokes and depression compared to controls. Moreover, ALS patients reported relevantly more often regular physical activity and their BMI was lower. The coexistence of coronary heart disease was associated with a relevantly faster disease progression. Intake of contraceptives was relevantly higher in controls compared with ALS patients.

conclusionsOur results suggest stroke, lower BMI, and regular physical activity as risk factors for ALS. Strokes could be a possible trigger of the pathogenetic pathway of ALS and the lower BMI with consecutively lower rate of hyperlipidemia supports the hypothesis of premorbid hypermetabolism in ALS patients. Coexistence of coronary heart disease possibly has a negative influence on respiratory involvement. Contraceptives could be beneficial due to a protective effect of estrogen. Information on influencing factors can help to elucidate the pathogenesis of ALS or provide approaches for possible therapeutic options.

Indexed as

Body Mass IndexDisease ProgressionExerciseAgedAmyotrophic Lateral SclerosisComorbidityContraceptive AgentsCoronary DiseaseDepressionFemaleGermanyHumansMaleMiddle AgedPrevalenceProtective FactorsContraceptive AgentsAmyotrophic lateral sclerosisCo-medicationComorbiditiesCourse of disease

Identifiers

PMID32266542
OpenAlexW3014745363

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.